Definiens Signs Agreement with Clarient to Offer Validated Solutions for Routine Clinical Pathology - Gilde Healthcare

Definiens Signs Agreement with Clarient to Offer Validated Solutions for Routine Clinical Pathology

3 februari 2014

MUNICH – Definiens, the global leader in image analysis for digital pathology and diagnostics announced today the signing of an agreement with Clarient Diagnostic Services, Inc.- which extends the use of Definiens’ automated image analysis software and solutions in Clarient’s validated clinical applications for immunohistochemistry testing in breast cancer. Definiens’ proprietary Cognition Network Technology® is core to automatically classify and quantitate key tissue features as part of Clarient’s Scope IA Platform offering to its pathology customers. 

“At Clarient, we combine world class pathology with innovation and our goal is to make a difference to physicians and their patients,” said Kenneth Bloom, MD, Chief Medical Officer, Clarient Diagnostic Services, Inc. “Our work with Definiens will enable us to offer high quality, robust readouts with fast turnaround time. This means physicians will have better patient insights for diagnosis.” 

“We are really pleased to work with Clarient on creating these validated applications for their routine clinical work. Running thousands of patient slides through our algorithms and seeing the computer-aided diagnosis in action is really gratifying,” said Thomas Heydler, CEO of Definiens. “No one else has done this on such a large scale.” 

Definiens’ Cognition Network Technology® was invented by 1986 Nobel prize winner Gerd Binnig and is unique in its ability to extract information from tissue images, a process known as tissue datafication™. Definiens applies the technology for solutions in discovery, preclinical, and diagnostic imaging. 

About Definiens

Definiens is the leading provider of image analysis solutions and data mining solutions for life science, tissue diagnostics, and clinical digital pathology. Definiens’ technology provides detailed biomarker readouts from slide images and enables the correlation of this information with other key clinical or genomic information, an approach known as Tissue Phenomics™. Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy. 
Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine, and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany and has its North American headquarters in Carlsbad, CA. Further information is available at www.definiens.com.

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate...
21 maart 2024

Gilde Healthcare sells RAD-x to a consortium of Swiss Life Asset Managers and Vesper Infrastructure Fund I

Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has reached a binding agreement to sell its majority stake in RAD-x to a consortium of Swiss Life Asset Managers and Vesper Next Generation...
18 maart 2024

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
29 februari 2024